[HTML][HTML] Obesity paradox in atrial fibrillation and its relation with the new oral anticoagulants
AIN Lima Filho, MC do Rego Barros… - Current Cardiology …, 2022 - ncbi.nlm.nih.gov
Obesity, a chronic disease established as a global epidemic by the World Health
Organization, is considered a risk factor for atrial fibrillation (AF), the most common …
Organization, is considered a risk factor for atrial fibrillation (AF), the most common …
Safety and efficacy of oral anticoagulants in extreme weights
J Chin-Hon, L Davenport, J Huang, M Akerman… - Thrombosis …, 2023 - Elsevier
Abstract Background The 2021 International Society on Thrombosis and
Haemostasis'(ISTH) recommends standard doses of apixaban and rivaroxaban regardless …
Haemostasis'(ISTH) recommends standard doses of apixaban and rivaroxaban regardless …
[HTML][HTML] Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Y Murakawa, T Ikeda, S Ogawa, T Kitazono… - Heart and vessels, 2020 - Springer
This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …
Association of low body weight with clinical outcomes in elderly atrial fibrillation patients receiving apixaban—J-ELD AF registry subanalysis
T Kadosaka, T Nagai, S Suzuki, I Sakuma… - … Drugs and Therapy, 2022 - Springer
Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …
Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review …
M Grymonprez, TL De Backer, S Steurbaut… - … Drugs and Therapy, 2021 - Springer
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …
Impact of body mass index and obesity on clinical outcomes in the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) …
Background In the ENSURE-AF study (NCT 02072434), the direct oral factor Xa inhibitor
edoxaban (edox) showed similar efficacy and safety vs enoxaparin-warfarin (enox-warf) in …
edoxaban (edox) showed similar efficacy and safety vs enoxaparin-warfarin (enox-warf) in …
[引用][C] Efficacy and Safety of Direct Oral Anticoagulants (DOACs) in Morbidly Obese Patients
PURPOSE: There is a paucity of clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy and …
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy and …
[HTML][HTML] Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
Purpose To investigate real-world prescribing trends and clinical outcomes based on body
mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This …
mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This …
[HTML][HTML] Healthcare resource utilization and costs of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
MR Weir, YW Chen, J He, B Bookhart, A Campbell… - Diabetes Therapy, 2021 - Springer
Introduction Nonvalvular atrial fibrillation (NVAF) is associated with a substantial economic
burden, particularly in patients with comorbid conditions. This study compared healthcare …
burden, particularly in patients with comorbid conditions. This study compared healthcare …